At a glance
- Originator Novo Nordisk
- Class Antihypercalcaemics; Small molecules
- Mechanism of Action Glycogen synthase kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 22 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in Denmark (unspecified route)
- 19 Sep 2001 Preclinical development for Type-2 diabetes mellitus in Denmark (Unknown route)